A Phase 2, Single-Blind, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine ± OMV When Administered at an 0-2-6-Month Schedule in Healthy Adolescents 11-18 Years of Age.

Trial Profile

A Phase 2, Single-Blind, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine ± OMV When Administered at an 0-2-6-Month Schedule in Healthy Adolescents 11-18 Years of Age.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2012

At a glance

  • Drugs Meningococcal vaccine group B; OMV
  • Indications Meningococcal group B infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Chiron Corporation; Novartis
  • Most Recent Events

    • 04 Jan 2012 Official title amended and actual patient number is 203 as reported by ClinicalTrials.gov.
    • 07 Dec 2011 Actual end date (Apr 2007) added, official title amended, aditional lead trial centre identified as reported by ClinicalTrials.gov.
    • 23 Apr 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top